Where Science Meets You
Scientific Advisors
Malak Althgafi, MD, MBA
Dr. Malak Althgafi, a Professor and Director of the Neuropathology Division and Fellowship. As a physician, pathologist, and molecular geneticist, her research endeavors are aimed at revolutionizing cancer treatment through precision medicine.
​
Beyond her academic and research pursuits, Dr. Althgafi is an entrepreneurial force, having founded two companies in the genomics space. These ventures further demonstrate her commitment to applying scientific discoveries to practical applications in cancer diagnosis and treatment. Dr. Althgafi’s role as an advisor to international organizations on genomics and precision medicine underscores her global impact on the field.
​​
​
.png)
Magid Abou-Gharbia, PhD, FRSC
Laura H. Carnell Professor of Pharmaceutical Sciences
Founding Director, Moulder Center for Drug Discovery Research
Magid Abou-Gharbia, Laura H. Carnell Professor and Founding Director of the Moulder Center for Drug Discovery Research at the School of Pharmacy, Temple University. Prior to Temple, he spent 26 years at Wyeth Pharmaceuticals (now Pfizer) where he was senior Vice President of Discovery. He led efforts of 500 scientists which were instrumental in the discovery of 10 marketed drugs, several are 1st in class includes: antidepressant Effexor, antibody-Drug Conjugate anti-cancer Mylotarg and 1st rapamycin analog anti-cancer Torisel. His efforts as Director of the Moulder Center (2008-2020) where he led School’s strategic initiative in achieving School’s research and entrepreneurial missions, resulted in over 40 patents,>$30 grant funding and 3 spinoff companies: https://www.youtube.com/watch?v=2yotuH6ZU0c
His efforts with the ACS in the mid 1990’s led to initiatives such as the ACS Heroes of Chemistry program, Pharma Leadership meetings, and joint ACS Mechem/EFMC events. Abou-Gharbia is credited with >125 issued US patents, >350 worldwide, 14 filed invention disclosure, 475 publications, invited lectures and presentations and has received numerous awards including 2 ACS Heroes of Chemistry awards for discovery of Toresil (2008) and Effexor (2014).
• Publications: 139 (Peer reviewed) https://scholar.google.com/citations?user=9lstbyMAAAAJ&hl=en&oi=ao
• Patents: 130 issued US Patents & >350 World Patents
https://patents.justia.com/inventor/magid-a-abou-gharbia
Viktor Voros, MD, PhD
Viktor Voros MD, PhD, Associate Professor, is a physician, clinical psychiatrist, and researcher. His major clinical and scientific interests are affective disorders and the psychiatric and psychological aspects of ageing and dementias. He is the co-founder of a Dedicated Research Centre in the field of psychiatry, neuropsychiatry and addictology. He serves as primary investigator in clinical trials, and he is a consultant for different pharmaceutical and biotech companies. He is a member of several scientific societies, and published his extensive research in different scientific journals, books and congresses.
​
.png)
Michael R. Barnes, PhD
I am a computational biologist with extensive experience in bioinformatics, genomics, and stratified medicine, spanning both industry and academia. After 13 years leading bioinformatics teams in pharmaceutical R&D, I transitioned to a new academic role leading the Centre for Translational Bioinformatics at Queen Mary University of London. My research bridges genomic biomarker discovery, drug development, and health data science, with a strong focus on translating omics insights into clinical and personalized medicine applications. As a Fellow of the Alan Turing Institute and Bioinformatics professor, I co-lead national and international initiatives leveraging AI and multi-omics to enhance disease stratification and therapeutic precision. My expertise in disease discovery aligns with PUER’s mission to apply and integrate high-dimensional biological data for personalized health optimization.
​
​